Sendurai Mani, Ph.D., Scientific co-founder used his years of experience in the field of cancer stem cells to ideate the development of a pipeline of anti-cancer drugs, thus forming Sathgen Therapeutics. Dr. Mani commenced his illustrious career following the completion of his PhD at the esteemed Indian Institute of Science in Bangalore, India. In 2009, he embarked on an impactful research journey by joining the Weinberg laboratory at the renowned Whitehead Institute, Massachusetts Institute of Technology, in Cambridge, MA. Dr. Mani, with his collaborators, spearheaded ground-breaking research that unveiled the pivotal role of epithelial-mesenchymal transition (EMT) in
spontaneous metastasis. Furthermore, he achieved a significant scientific milestone by being the first to demonstrate that cancer cells can acquire stem cell properties. This seminal finding has garnered over 9,500 citations, shedding light on the importance of his work in the field on cancer.
Dr. Mani’s exceptional contributions have garnered him numerous prestigious awards, including the V-Scholar and American Cancer Society Research Scholar awards. Additionally, he holds the distinguished honor of being an elected member of the scientific research honor society Sigma Xi and a fellow of the esteemed American Association for the Advancement of Sciences (AAAS).

Dr. Mani’s vision for the company:

The remarkable progress in the field of cancer diagnosis and treatment has undoubtedly improved the survival rates of cancer patients, enabling them to lead longer lives. However, a concerning aspect that persists is the development of metastasis, tumor relapse, and resistance to existing therapies. These challenges are predominantly due to the presence of cancer stem cells within tumors.

Fortunately, there is hope on the horizon. The emergence of Sathgen’s drug presents a promising solution to address these issues. By specifically targeting and eliminating cancer stem cells, this
innovative drug holds potential revolutionize the landscape of cancer therapies, offering a new avenue to combat the fundamental drivers of metastasis ad therapy resistance. The successful
implementation of Sathgen’s drug would mark a significant breakthrough in cancer treatment, providing renewed optimism for cancer patients.”